Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. 

LimFlow recently earned FDA approval for its transcatheter deep-vein arterialization system for the treatment of chronic limb-threatening ischemia. Inari, which has previously focused on venous thromboembolism, believes LimFlow's total addressable market could be worth over $4bn annually, with no direct competition in sight.

The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.

Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.